Systemic administration of indomethacin (IDM) causes inflammation of the small intestine. Although the pathogenic events of IDM are more complex, it is considered that suppression of prostaglandin synthesis, mitochondrial damage and oxidative stress response are involved in it.
Previous studies using animal models of bowel disease involving IDM-induced intestinal injury, trinitrobenzene sulfonic acid (TNBS)-induced colitis and dextran sulfate sodium-induced colitis have shown that the enteropathy is associated with the alteration of hepatic cytochrome P450 (CYP) and been suggested the relationship of the entering bacterial endotoxin into portal vein according to an increase of intestinal epithelium permeability. [7] [8] [9] In contrast with CYPs, little is known about the expression of hepatic transporters in bowel injury, although drug transporters as well as metabolizing enzymes play an important role in the disposition of most drugs.
Organic anion transporting polypeptides (Oatp), located in the liver sinusoidal membrane, take part in the hepatic uptake of bile acids, peptide hormones, steroid hormones and a variety of drugs. 10, 11) Multidrug resistance-associated protein 2 (Mrp2), located in the liver canalicular membrane, excretes a variety of organic anions including endogenous glutathione (GSH), GSH-conjugates and glucuronides into bile. 12, 13) Interplay between these influx and efflux transporters is fundamental to the biliary elimination or enterohepatic recirculation of endogenous and exogenous compounds. [14] [15] [16] The aim of this study is to characterize the alteration in these hepatic organic anion transporters in rats with IDM-induced injury to the small intestine. The hepatic transporter function was evaluated by a pharmacokinetic study of bromosulfophthalein (BSP), and the expression of hepatic transporters for BSP was also evaluated in control and IDMtreated rats. Inflammatory mediators in the portal plasma were traced as causal candidates ultimately affecting hepatic transporter expression.
MATERIALS AND METHODS
Chemicals IDM was purchased from Wako Pure Chemical Industries (Osaka, Japan). BSP was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.). Other chemicals and solvents used were of the highest quality commercially available.
In Vivo Experimental Procedures Male Sprague-Dawley rats (Japan SLC Inc., Shizuoka, Japan) weighing 235-290 g (7-8 weeks old) were used throughout the experiments. Rats were housed in an air-conditioned room (25°C) under a 12 h light-dark cycle for at least 1 week before use. Food (the MF diet, standard laboratory diet commercially available, Oriental Yeast Co., Ltd., Tokyo, Japan) and water were given ad libitum. The rats were injected intraperitoneally with 8.5 mg/kg/d IDM (dissolved in 5% sodium bicarbonate solution) for 3 d. Then, 24 h after the final injection, the rats were maintained under ether anesthesia, and kept warm under a lamp throughout the experiments. The femoral artery and vein were cannulated with polyethylene tubing (PE-45 and 30) for BSP administration and blood collections, respectively. The common bile duct was cannulated with PE-10 tubing to collect bile. After intravenous (i.v.) administration of BSP (10 mmol/kg), blood and bile samples were obtained at designated times. After the pharmacokinetic experiments involving BSP, portal blood samples were collected, and intestines and livers were removed from the rats.
Down-Regulation of Hepatic Transporters for BSP in Rats with
Bile and blood concentrations of BSP were determined from the difference in absorbance at 570 nm and 630 nm after alkali treatment by the method described by Molino et al. 17) All procedures were approved by the Animal Care Committee of the Graduate School of Pharmaceutical Sciences, Chiba University.
Western Blot Analysis Hepatic plasma membrane fractions were prepared as described previously 18) with modification. Briefly, the liver was homogenized with glass/glass homogenizer, and the liver homogenate was centrifuged at 1500 g for 15 min. The pellet was suspended in 70% (w/w) sucrose of 2.5-fold volume and overlaid with 44% (w/w) sucrose and 36.5% (w/w) sucrose, was centrifuged at 100000 g for 90 min at 4°C. The plasma membrane fraction was obtained from interface between 44% and 36.5% sucrose, and its suspension of the fraction was stored at Ϫ80°C.
25 mg protein of the hepatic plasma membrane fraction or 50 mg protein of the hepatic homogenate were loaded onto an 8.5 or 12.5% polyacrylamide slab gel containing 0.1% sodium dodecyl sulfate and then transferred to an Immobilon-P Transfer Membrane filter (Millipore Corporation, Bedford, MA, U.S.A.) by electroblotting. The membrane was blocked with Tris-buffered saline with 0.05% Tween 20 (TTBS) containing 3% bovine serum albumin (BSA) for 60 min at room temperature and probed for 60 min at room temperature with anti-Mrp2 antiserum (1 : 5000) or anti-Oapt1b2 antiserum (1 : 3000) diluted with TTBS containing 0.1% BSA. The Mrp2 antibody was previously described.
19) The Oatp1b2 antibody was kindly provided by Dr. Yuichi Sugiyama at The University of Tokyo. The membrane was then allowed to bind anti-rabbit antibody (1 : 3000) (Santa Cruz Biotech, Inc., Santa Cruz, CA, U.S.A.) diluted with TTBS containing 0.1% BSA, and finally optimal intensity of bands was analyzed using an enhanced chemiluminesence (ECL) kit (Amersham Bioscience Corp., Piscataway, NJ, U.S.A.).
Semiquantative Real-Time RT-PCR Total mRNA was prepared from the liver using RNA-Solv ® reagent (OMEGA Bio-tek, Inc., Doraville, GA, U.S.A.). Reverse transcription was performed with 1 mg of the total RNA using Takara RNA PCR TM kit (AMV) Ver. 3.0 (Takarabio, Shiga, Japan). Real-time polymerase chain reaction (PCR) was performed to quantify the mRNA expression relative to b-actin using the qPCR TM Mastermix for SYBR ® Green I (Eurogentec SA, Seraing, Belgium). Real-time RT-PCR amplification was determined utilizing an ABI Prism 7000 machine (Applied Biosystems, Foster City, CA, U.S.A.). All samples were performed with duplication. The primer pairs used are listed in Table 1 .
Measurements of Intestinal Wet Weight, ALP Activity in Mucosa, Serum ALT and AST Activities Jejunum and ileum injuries were evaluated using a 7 cm section about 10 and 25 cm below the pylorus, respectively. ALP activities in the small intestine were measured according to the method described by Bowers et al. 20) with modification. 21) Liver injury was evaluated by measuring serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, which were determined in combination with the method described by Tonhazy et al., 22) Reitman et al. 23) and Katsuki et al. 24) with some modification.
Measurements of Cytokines and Nitric Oxide in Portal
Blood Tumor necrosis factor a (TNFa), interleukin (IL)-1b and -6 were determined in the portal plasma by enzymelinked immunosorbent assay kits (Biosource International, Inc., Camarillo, CA, U.S.A.). Nitric oxide (NO) in portal plasma was determined as its metabolites (NO 2 Ϫ ϩNO 3 Ϫ ) by the Griess reaction with some modification. 25) Data Analysis BSP concentration-time data (C p (t)) obtained from the individual experiments were fitted to the following Eq. 1 using a nonlinear least squares program, MULTI edited by Yamaoka et al., 26) and the parameters for a typical 2-compartment model were calculated.
The area under the plasma concentration-time curve (AUC) was calculated by the linear trapezoidal rule and extrapolation to infinity (tϭϱ) with b. Total clearance (CL total ) and the biliary excretion clearance (CL bile ) were calculated from dose/AUC 0-ϱ and X bile (t)/AUC 0-t , where X bile (t) is the cumulative biliary excretion of BSP, respectively.
Statistical Analysis All data were expressed as the meanϮstandard deviation. Statistical analyses were performed with an unpaired t-test or one-way analysis of variance followed by the Dunnet's test using a program, InStat 3 (Graphpad Software, Inc., San Diego, CA, U.S.A.).
RESULTS

Physiological and Biochemical Parameters in Control and IDM-Treated Rats
Intestinal injury induced by repetitive IDM treatment for 3 d produced a significant reduction in jejunal wet weight (Table 2) . ALP activities per mg protein of jejunal and ileal mucosae were also reduced ( Table 2) while no significant difference was observed in their protein contents between control and IDM-treated rats (data not shown). The ALT level was significantly increased in IDMtreated rats, while there was no significant difference in the plasma AST level ( Table 2) .
Effect of Repeated IDM Treatment on Plasma Concentration and Biliary Excretion of BSP The plasma BSP concentration-time profiles and the corresponding pharmacokinetic parameters in control and IDM-treated rats are shown in Fig. 1 and Table 3 . Although no significant difference was observed in the initial distribution volumes [Dose/(AϩB)] in Eq. 1, the rate constants a and b for the distribution and elimination phase in IDM-treated rats were significantly reduced to 70.1 and 39.9% of the controls, respectively, and total body clearance (CL total ) was also reduced to 54.1%. The maximum biliary excretion rate of BSP was reduced to 50% of the control (as seen in the slope at 5-10 min in Fig. 2A ) without affecting bile flow rate (Fig. 2B) . The cumulative biliary excretion at 60 min after BSP injection was 94.3 and 79.2% of the dose in control and IDMtreated rats, respectively (Fig. 2B) . The biliary clearance (CL bile ) of BSP in IDM-treated rats was reduced to 45.7% of the control (Table 3) .
Effect of Repeated IDM Treatment on Hepatic Oatp1b2 and Mrp2 Expressions BSP is taken up via hepatic Oatp1a1 and Oatp1b2, rapidly conjugated with GSH and subsequently excreted into bile via Mrp2. 10, 27, 28) In IDMtreated rats, the expression of Oatp1b2 and Mrp2 in the plasma membrane fraction was reduced to 30.2 and 39.3% of the controls, respectively (Figs. 3A, C) . This reduction was also observed in hepatic homogenate (Figs. 3B, D) . Messenger RNA levels of Oatp1a1, Oatp1b2 and Mrp2 were also significantly reduced to 23.4, 13.3 and 34.6% of the controls, respectively (Fig. 4) . Furthermore, mRNA level of other Oatp family member, Oatp1a4 was markedly reduced to 3.2% of the control. Table 4 , no significant difference was observed in the portal plasma levels of TNFa, IL-1b and IL-6 between controls and IDMtreated rats, while NO 2 Ϫ ϩNO 3 Ϫ levels were markedly increased, up to 6.5-fold.
Evaluation of Portal Inflammatory Mediator Levels in Control and IDM-Treated Rats As shown in
Time-Course of Intestinal Injury, Portal NO Level, Hepatic Transporter Expression and Hepatic Injury Following Repeated IDM Treatment Small intestinal injury assessed by ALP activity was observed on the first day after IDM treatment and was aggravated by repeated IDM-treatment (Fig. 5A) . The increase in the portal concentration of NO following IDM treatment was in parallel with the intestinal injury (Figs. 5A, B) . Hepatic Oatp1b2 and Mrp2 expressions reduced to nearly 50% of the untreated rats at day 2, after the induction of intestinal injury and the increase in NO levels (Figs. 5C-F) . Although plasma ALT and AST levels remained unchanged until day 2, a minor, but significant, increase in the ALT level was observed at day 3 (Fig.  5G) . 
DISCUSSION
The present study demonstrated that IDM-induced intestinal injury caused a reduction in biliary BSP excretion (Figs. 1 and 2, Table 3 ) as well as the suppression of hepatic Oatp1b2 and Mrp2 expressions (Fig. 3) . This is the first report connecting an intestinal injury with a functional change of hepatic transporters in rats. As Oatp1b2 and Mrp2 are involved in the biliary excretion of BSP, we focused on these transporters. However, other transporters are also involved in it. In fact, BSP is also a substrate of Oatp1a1, a hepatic uptake transporter.
27) Thus, we also investigated the mRNA (Fig. 4) and protein (data not shown) expressions of Oatp1a1 and found that its expression was decreased just like Oatp1b2. The competitive inhibitory effect of IDM on the BSP transport also should be considered because Oatp1b2 and Mrp2 are also responsible for the biliary excretion of IDM and its glucuronide. 29, 30) However, a pilot study showed that it seemed to be minor because a coadministration of IDM (1.0 mg/kg) at 2 h prior to BSP injection affected neither its plasma elimination nor biliary excretion (data not shown). The reduction in the mRNA levels of Oatp1b2 and Mrp2 was similar to that in their protein levels (Fig. 4) , suggesting that transcriptional down-regulation and/or accelerated mRNA degradation is the cause of their down-regulations, rather than changes in translational efficiency or altered intracellular sorting of the transporters as reported elsewhere. 31, 32) A previous study reported that hepatic injury, for example lithocholic acid-or carbon tetrachloride-induced injury, results in the alteration of expression of many transporters. 33, 34) IDM could also adversely induce hepatopathy as described in the package insert. However, in this study, the down-regula- tion of Oatp1b2 and Mrp2 obviously preceded plasma ALT elevation (Figs. 5C-G), suggesting that hepatopathy was not induced by IDM treatment but hepatic toxicity was associated with the reduced function of hepatic transporters.
Administration of the endotoxin stimulates an endotoxinspecific receptor, Toll-like receptor (TLR) 4, and induces a strong immune response consistent with increased expressions of proinflammatory cytokines, TNFa, IL-1b and IL-6, resulting in hepatotoxicity and the subsequent down-regulation of hepatic CYPs and transporters expression. 35, 36) Previously, we reported that the portal endotoxin level was increased 3-fold in the same rat model. 9) Thus, it was suggested that the down-regulation of hepatic Mrp2 and Oatp family observed in this study related with the endotoxin inverted from intestine. Kawaguchi et al. reported that TNBStreated rats also had an elevated portal endotoxin level, followed by the reduction of hepatic Mrp2, although inflammatory cytokine levels were unchanged. 37) According to their report, the pretreatment with antibiotics, polymyxin B prevented from the change of hepatic Mrp2 in TNBS-treated rats, suggesting the involvement of the endotoxin invasion in the suppression of the transporter. In the present study, there is no change of proinflammatory cytokines (Table 4) . Recently, we reported that TLR4-mutant mice also showed the down-regulation of hepatic CYPs with an elevated endotoxin level in portal plasma after IDM treatment, although the extent of the reduction was smaller than that in wild-type mice.
38) Therefore, it is considered that not only the endotoxin derived from the injured bowel but also other factors are involved in the interaction between the intestine and the liver.
In the present study, we have shown the increased NO level in the portal plasma, suggesting it may be one of factors affecting the expression levels of hepatic transporters. The present results also showed the time-dependent increase in the portal NO level was closely correlated with the degree of intestinal injury (ALP activity) and the hepatic transporter down-regulation (Table 4 , Figs. 5A-F). It can be derived from extra-hepatic organs, such as the injured intestine in vivo. Actually, IDM-induced enteropathy causes an induction of iNOS in jejunal mucosa. 39) Although the half-life of NO is very short, i.e. less than 10 s, it may be long for NO produced in intestine enough to reach the liver, because these organs are very close. Moreover, NO subsequently produces more stable S-nitrosothiols, e.g., S-nitrosohemoglobin and S-nitrosocysteine, which act as an NO donor in the presence of iron or copper ions. [40] [41] [42] [43] Also, previous studies have reported that NO functions as a negative modulator of nuclear factors, e.g. glucocorticoid receptor which regulates a number of transporter gene expression. 44, 45) By this mechanism, NO may affect the transporter expression levels. It also should be considered that IDM directly affected the hepatic expression of transporters, resulting in its reduction. However, our pilot study showed inhibition of iNOS by aminoguanidine partly attenuated the reduced expression of Mrp2. In addition, our previous study showed IDM treatment reduced the expression of CYPs affected by NO. 9) Thus, overflow of NO from the injured intestine is partly responsible for the down-regulation of hepatic transporters.
In conclusion, we have demonstrated that the hepatobiliary transport function for organic anions is down-regulated accompanied with IDM-induced intestinal injury without hepatopathy. Gut-derived NO released into the portal vein may be one of the candidate molecules involved in the down-regulation of hepatic transporters.
